Business Development

Partnering is a key part of Adagene’s growth strategy. We seek to partner to utilize Adagene’s unique skill set to develop therapeutics for new target classes that, if successful, will radically change the treatment paradigm within the target indication.

Adagene also plans to partner our lead antibody programs in combination trials. Due to the cross species reactive nature of the Adagene antibodies, we can take advantage of highly predictive models where we exhibit strong additive or synergistic behavior into the clinical setting.

For further information, please contact [email protected].

?Copyright-Adagene 2019
有没有推荐赚钱的软件 彩金捕鱼季免费下载 四川金7乐当日开奖查询 股票涨价下跌 海南飞鱼中奖 广西11选5下载 集中盈炒股平台正规 850棋牌类游戏 杠杆平台 富贵庄园官网下载 上交所股票期权交易